enrolled in the Registry with evaluable pregnancy data from the pharmacovigilance database were included. Here, we report the number, treatment status and outcomes for these patients. RESULTS: As of December 2018, 37 patients with aHUS had 40 pregnancies recorded after consenting to enrollment in the Registry. In 7 cases, the outcome was not reported, and in 2 cases, the pregnancy was still ongoing at the time of data cutoff. In total, 31 pregnancies had known outcomes; 22 in those with eculizumab exposure and 9 in those without (Table). There was a higher proportion of live births in non-exposed vs eculizumab-exposed patients (78% vs 55%) and more elective terminations in eculizumab-treated patients (36% vs 11%). The relapse proportion in eculizumab-exposed patients was lower than in non-exposed patients (5% vs 22%). No neonatal malformations were reported within 3 months. Complement mutations were found in 55% of tested patients. CONCLUSIONS: Real world evidence from the aHUS Registry did not identify an increased risk of poor outcomes or foetal abnormalities in pregnancies exposed to eculizumab, with the miscarriage proportion consistent with the general population (up to 20%[1]). This indicates that elective termination of pregnancy in 36% of patients with aHUS may not be justified by the potential for poor outcomes in these patients. Further evaluation of this subpopulation of aHUS is ongoing. Reference: [1] Griebel CP, et al. American Family Physician 2005;72(7):1243–50 SP076 CLINICAL FACTORS FOR PREDICTION OF MILD COGNITIVE IMPAIRMENT IN PATIENTS RECEIVING DIALYSIS Jin-Bor Chen 1 , Li Lung-Chih 1 , Lee Wen-Chin 1 , Chang Chiung-Chih 2 , Chiu- Hua Chen 1 1 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan and 2 Chang Gung Memorial Hospital-Kaohsiung and Chang Gung University College of Medicine, Kaohsiung, Niao Song District, Kaohsiung City, Taiwan INTRODUCTION: To examine possible mutual interactions of various factors contributing to cognitive impairment in dialysis patients. METHODS: A total 48 patients receiving dialysis with subjective memory complaints in outpatient clinic were recruited from 2015 to 2017. Demographics, circulating uremic toxin concentrations (small water-soluble, protein-bound, medium-sized solutes), miRNA concentrations and nerve injury protein concentrations were collected and measured. Clinical dementia rating (CDR) scores was used to stratify the functional scores of the patients.Receiver operating characteristic(ROC) analysis was used to evaluate diagnostic test performance for predicting dichotomous results, cumulative ROC analysis to examine the interactions between clinical factors. RESULTS: On individual analysis, the area under curve(AUC) was more than 0.7 for hemoglobin and age. On cumulative ROC analysis, the major predictors of mild cognitive impairment were hemoglobin, age, sex, homocysteine, neuron-specific enolase and miR-486. The cumulative AUC on combining hemoglobin, age, and miR- 486 was the highest (0.897, 95% confidence interval 0.806–0.988). Two dichotomized variables reached 81.82% sensitivity and 86.67% specificity, with the likelihood ratio for positive and negative results being 6.14 and 0.21, respectively. CONCLUSIONS: Hemoglobin, age, and miR-486 are the major predictors for mild cognitive impairment in patients receiving dialysis. SP077 LONGITUDINAL CHANGES OF PAI-1, MMP-2 AND VEGF IN PERITONEAL EFFLUENTS AND THEIR ASSOCIATIONS WITH PERITONEAL SMALL-SOLUTE TRANSFER RATE IN NEW PERITONEAL DIALYSIS PATIENTS na hao 1 , Ting-Yu Chiou Terry 2 , Yang Hong-Tao 1 , Chen Jin-Bor 3 1 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 2 and Chang Gung University College of Medicine, Kaohsiung, China and 3 Chang Gung University College of Medicine, Chung Shan Medical University School of Medicine, Kaohsiung, China INTRODUCTION: Patients on peritoneal dialysis (PD) encounter peritoneal functional and structural alterations. It is still unknown whether levels of plasminogen activator inhibitor type 1 (PAI-1), matrix metalloproteinases (MMP)-2, and vascular endothelial growth factor (VEGF) exhibit dynamic changes in peritoneal effluents. The aim of present study was to investigate the longitudinal changes in these biomarkers in PD patients and their association with peritoneal small-solute transfer rate (PSTR). METHODS: This prospective, single-center cohort study included 70 new PD patients. The presence of PAI-1, MMP-2, and VEGF in peritoneal effluents was measured regularly after PD initiation. The association between those biomarkers and 4-hour effluent:plasma creatinine ratio (PSTR) was analyzed. RESULTS: Longitudinal follow-up showed a tendency for PAI-1 (p < 0.001) and VEGF (p = 0.04) to increase with the duration of PD. Both PSTR at baseline and PSTR at 2 years significantly associated with PAI-1, MMP-2 and VEGF levels at baseline. PSTR at 2 years also associated with the MMP-2 level at 6 months and PAI-1 level at baseline.. CONCLUSIONS: The present study illustrated a positive association of PSTR with selected biomarkers in peritoneal effluents observed over a 2-year period. SP078 SEVERE HYPERCALCEMIA: NEW ETIOLOGIES FOR AN OLD PROBLEM. THE NEPHROLOGICAL MANAGEMENT jose luis lerma 1 , E Ruiz-Ferreras 1 , Miguel S anchez-Jauregui 1 , Martin-Centellas J 1 , Martin-Arribas A 1 , K Rivero 1 , J Sebastia 1 , Gonzalo Delgado Lapeira 1 , Ja Menacho 1 1 HOSPITAL UNIVERSITARIO, SALAMANCA, Spain INTRODUCTION: Hypercalcemia is a metabolic disorder that can cause malignant ventricular arrhythmias, intestinal motility problems, decreased level of consciousness, neuromuscular irritation and, in very advanced situations, death. Although in its mild forms it is very frequent and causes mild symptoms, its severe forms are expression of serious pathologies , and can be the initial analytical data or the consequence of aggressive therapies or vitamin poisonings or prescription errors. It is interesting to evaluate the etiologies, and the Nephrologist therapies of a Reference Salamanca University Hospital since it may be useful for future approaches Aims: 1.To establish etiology of severe hypercacemia 2.To evaluate specific Nephrological/dialytic treatment and follow up. METHODS: Data on severe hypercalcemia in which Salamanca University Hospital Nephrology Service was consulted were collected prospectively during the 24-month interval. A total of 30 patients (12 men, 18 women) presented Ca> 11.5, with a maximum of 19.5 .Therapy and results were follow up Statistical Analysis:SPSS 15.0 RESULTS: Tumoral: 18/30 (60%) were related to neoplasms with direct bone involvement (multiple myeloma) or metastasis (Ca Mama, Lymphomas, Ca prostate). In some very frequent cancers, such as breast cancer, it was the first manifestation that led to hospital admission and diagnosis and subsequent treatment. Most requent causes were Hematological Neoplasms, especially the Multiple Myeloma that occupies the first rank with a total of 5 cases followed by Non-Hodgkin Lymphomas in 2 cases, and implied a poor prognosis as expression of highly advanced metatastatic bone disease. Mortality in this group were 22%. Hemodialysis was done in 4 patients (22%). Biphosphonates :100% Non tumoral etiologies (12/30: 40%) were Calcifediol Intoxication (n:5; 16,6%)(due to misinterpretation of Guidelines), iatrogenic (n:4) and miscelaneous (n:3). Hemodialysis :0 . Biphosphonates :100% Mortality: 0% Acute Renal Failure: 15% (it is interesting that 2 vitamin D intoxication in CKD patients, induced a Glomerular Filtration decreased >45%). CONCLUSIONS: 1)Severe Hypercalcemia is a serious increasing metabolic disorder that need Dialytic Management in some cases. 2)Main etiology is neoplasms (60%), of hematological origin (38%),and solid tumor (bone metastasis)(62%) 3)Vitamin D intoxication (calcifediol) was an important understimate reversible cause (16%), especially in patients with previous CKD or liver disfunction. 4) Severe Hypercalcemia Management require multidisciplinar approach (Nephro- Oncology) SP079 PLASMA EXCHANGE VERSUS DOUBLE FILTRATION PLASMAPHERESIS IN THE TREATMENT OF ANTI- NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS INVOLVED WITH SEVERE RENAL FAILURE Lu Cheng 1 , Gou Shen-Ju 1 , Ren Qian 1 , Fu Ping 2 1 West China Hospital of Sichuan University, Chengdu, China and 2 West China Hospital of Sichuan University, Chengdu, Chengdu, China INTRODUCTION: Previous studies have shown that plasma exchange (PLEX) and double filtration plasmapheresis (DFPP) are effective treatments in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) involved with severe renal failure. However, whether PLEX and DFPP have similar effects in AAV is not clear. So the study aimed to compare the therapeutic effectiveness of PLEX and DFPP in AAV patients with severe renal failure. METHODS: This study was performed by analyzing the clinicopathological and follow-up data of 42 AAV patients, including 21 with PLEX (hereafter PLEX group) and 21 with DFPP (hereafter DFPP group), in West China Hospital of Sichuan University during Jan 2013 to Jun 2017. The effectiveness of PLEX and DFPP was assessed according to renal response and outcome. All data from group PLEX and group DFPP was analyzed by difference analysis and survival analysis. RESULTS: The baseline clinical data and basic treatment regimens showed there were no significantly difference between the patients of PLEX group and DFPP group. In- hospital mortality of patients in both group were 19.0% (4/21).After basic treatment with PLEX or DFPP, serum creatinine (Scr) obviously decreased, but there were no significantly differences between group PLEX and DFPP. Kaplan-Meier survival analysis showed that PLEX or DFPP made no difference to survival of patients (p=0.322). However, the patients in PLEX group had a significantly better renal survival than the patients in DFPP group (p=0.003<0.05). The results of Cox’s proportional hazards model revealed age was independent significant prognostic factors affecting the survival in AAV patients, and whether PLEX or DFPP treatment, doi:10.1093/ndt/gfz103 | i389 Nephrology Dialysis Transplantation Abstracts Downloaded from https://academic.oup.com/ndt/article/34/Supplement_1/gfz103.SP078/5515008 by guest on 17 February 2023